ABSTRACT BACKGROUND: Early detection of cystic fibrosis (CF) by newborn screening (NBS) reduces the rate of avoidable complications. NBS protocols vary by jurisdiction and the cost effectiveness of these different protocols is debated.
INTRODUCTION
Cystic fibrosis (CF) represents one of the most common and disabling diseases in the Caucasian population [1] [2] . In Canada, its incidence is estimated approximately at 1/3600 live births [3] and 1/2500 in the province of Quebec [4] .
With the advent of new treatment protocols and nutritional support, most children with CF live to adulthood, with a median age of survival of 48.1 years in Canada [5] . However, age at initial CF diagnosis remains a major problem. Indeed, in the absence of NBS, the median age at initial diagnosis is approximately 7 months while the mean age is 3.8 years, usually following numerous repetitive medical consultations for airway diseases [5] [6] .
Early detection of CF, i.e. before the appearance of the first symptoms, has a beneficial effect on the evolution of the disease by allowing earlier preventive treatment and follow-up [2, [7] [8] . It has been shown that a diagnosis made before 2 months of life is associated with improved nutritional status, better growth, fewer hospitalizations and a decreased rate of complications throughout infancy, childhood, and adolescence, and better cognitive functions [9] [10] [11] . Furthermore, early diagnosis and treatment are believed to reduce expenses and parental anxiety associated with failure to thrive and other symptoms [8] .
Research has showed the potential benefits of early diagnosis and treatment of CF through NBS. In a retrospective UK cohort, Sims et al. (2007) showed that the cost of therapy for patients diagnosed through a NBS program (31 CFTR mutation panel) was significantly lower (60-400%) than the costs of therapy of clinically diagnosed patients of the same age-range.
The difference was attributed to lower treatment costs and reduced hospital admissions for invasive therapies. Indirect costs and disruption of family life were also expected to be lower among screened infants.
As a result, NBS for CF has been proposed as a useful approach to improve the quality of life of patients and their family and has been promoted by several Genetic Societies including the American College of Medical Geneticists, the American College of Obstetricians and
Gynaecologists [8, [12] [13] , as well as by the US Center for Disease Control [2] . Since these recommendations, all US States have initiated CF NBS programs. In Canada, as of 2013, five provinces (Alberta, British-Columbia, Manitoba, Ontario and Saskatchewan) have implemented a NBS program for cystic fibrosis. [4] [5] .
One of the reasons that some jurisdictions in Canada have delayed implementing a screening program is the lack of information regarding the most cost/effective screening strategy amongst the many existing options. Indeed, in spite of the many cost effectiveness studies that have shown that CF NBS is cost effective, no study has compared all together the different screening algorithms that are realistically implementable. Also, no study has tested various immunoreactive trypsinogen (IRT) cutoffs as a first tier test with or without the different CFTR mutation panels commonly used [14] [15] [16] [17] . In addition to identifying the optimal screening strategy, our study aims to compare the cost effectiveness of 20 NBS algorithms using two cutoffs (96 th percentile and 99.5 th percentile) of IRT as first tier, varying the CFTR mutations panels, and comparing these algorithms to the no-screening option.
METHODS

Overview
A Markov decision model was built using the Clumeq supercomputer network-running SCHNAPS platform [18] [19] [20] to simulate the cost effectiveness of 20 CF-screening strategies and to compare these strategies to the current situation (absence of universal CF neonatal screening) in the Quebec public health care setting. Comparisons were made for a hypothetical CF NBS program spanning over 5 years and targeting newborns in the province of Quebec [21] . We assumed that this screening program would be integrated into the existing Quebec NBS program [22] . Outcomes considered were the direct costs borne by the Quebec universal health care system and the number of CF cases detected.
Modeling
The simplified model structure is presented in Figure 1 . The model, divided into cycles of one year each, has two starting branches: 1) "Absence of NBS strategy "and 2) "NBS strategy".
The model assumed a CF incidence of 1 in 2500 newborns (with 86 000 births, 35 CF cases are expected each year) [4] . The model excludes those diagnosed clinically with a meconium ileus (MI) as they would have been diagnosed at birth even in the absence of neonatal screening [16, 23] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Under "Absence of NBS", newborns have an annual probability of being diagnosed with CF based on symptoms or a family history. These probabilities were modeled according to data from the Quebec patients of the Canadian cystic fibrosis patient data registry (CPDR) [24] .
This population consists of 174 children with CF without MI who were born since the year 2000. The model considered also that 75 (50-100) sweats tests were performed in children without CF for each child with a diagnosed CF [25] . This average estimate is similar to the one observed in Quebec according to data recently published by the Quebec National Institute of Public Health from an analysis of data from laboratories that perform sweat tests [4] , and which is around 72 sweat tests per child with CF.
Under "NBS strategy", screening is proposed to all newborns. As we assumed that a screening program would be integrated into the existing neonatal newborn screening program
for genetic diseases our model considered a similar screening coverage rate of 99 % of all newborns [22] . Newborns that were not screened because their parents declined screening have the same probability of being diagnosed clinically as those in the "Absence of NBS strategy" option. When parents accept NBS, cases of CF are detected according to the performance of the test used (sensitivity and specificity). The model considered the compliance rate for recall samples if a second IRT is required [16] . We made the assumption that cases of CF would be detected within the first three months in the screening options. For missed cases, we assumed the same probability of being diagnosed clinically as for those in the "Absence of NBS strategy" option.
In addition, we assume that if a child with CF is diagnosed, he is followed in a CF specialized center from that point on. Each year, this child has a probability of developing CF-associated complications that lead to medical visits and hospitalizations. Children with CF who did not yet receive a diagnosis of CF might also experience CF-associated complications but with a higher probability compared to those already diagnosed [9, [26] [27] [28] In all options, there is a probability at the end of each year cycle that the child (with or without CF) has died. Because the survival of children with CF under 5 years of age in Quebec and Canada has been of approximately 100% over the last decade according to the CPDR, we attributed to all children (with or without CF), the same "all-cause death probability", which is an estimate of the average death risk based on age according to data from the Quebec Institute of Statistics. In sensitivity analyses, we used 5-years survival rates of 95% and 98% for children with CF assuming the same death probability each year over the 5 years.
The input parameters are presented in Table 2 . They are based on published data, Quebec data extracted from the CPDR as well as on experts' opinion. Parameters were modeled in order to reflect the event probabilities in screened and unscreened children with CF.
Newborn screening options
Screening algorithms are presented in Table 1 . For all screening algorithms, the model takes into account the compliance rates at each screening step. For the first tier test (IRT1), the model assumed a coverage rate of 99%, similar to that of the existing Quebec newborn screening program for genetic diseases [22] . The model considers, for all screening algorithms that include the DNA analysis, the probability of accepting genetic counseling as well as the probability of consent to a DNA test [15, 29] . 
Costs
Direct medical costs that were considered related to the screening and treatment of cases of CF over a 5 year time horizon under the perspective of the Quebec public health care system.
The costs of screening included the cost of the tests (IRT, PAP, DNA, and sweat test), genetic counseling for the pre-and post DNA testing options, and the physician fees for the tests' interpretation. The costs of disease management included the cost of medical visits, hospitalizations, laboratory, imaging and electrophysiological tests, medications (antibiotics, corticosteroids, etc.) and special diets (vitamins, pancreatic enzymes, oxygen). Quantification of medical and paramedical services used by CF infants was estimated using data from children with CF without MI included in the CPDR database. Services used before clinical diagnosis of CF were estimated from data of 44 Quebec children diagnosed before 5 years of age and for whom data on services used were available. Quantification of services after clinically diagnosis was estimated using data of 174 Quebec patients of the CPDR born since 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 the year 2000. As NBS for CF is not implemented in the Province, quantification of services used by children diagnosed through NBS was estimated using data from 126 children with CF originating from Alberta, Saskatchewan, British-Columbia and Ontario, provinces that have already implemented the NBS for CF.
All unit prices are Quebec public provincial average prices calculated from governmental databases. The lowest reimbursable price for medications by the provincial public insurance scheme RAMQ (RAMQ, Manuel des pharmaciens) [30] and the average price paid by the RAMQ to physicians were considered (RAMQ, manuel des médecins spécialistes) [20] . Unit prices for activity centers were calculated using the Quebec financial and operational data base (SIFO). This was applied to non-medical services, including ancillary services.
Provincial technical units were used for laboratory and imaging tests to calculate their unit prices. All SIFO unit prices were over-headed using the direct approach in order to take into consideration the support activity centers [31] . As the PAP assay is not available in Canada, its cost was estimated from the documentation provided by a scientific adviser from a French biotechnology company (Dynabio), which manufactures and markets the PAP assays.
The fiscal year 2011-2012 was used to calculate all costs. Costs were discounted at a rate of 3%. Detailed estimates of costs used in the model are presented in Table 2 . 
Sensitivity analyses
Univariate and multi-way sensitivity analyses were performed using the parameters suspected to have an impact on outcomes as detailed in Table 2 . One-way sensitivity analyses were performed to evaluate the eventual impact of each single parameter on the results. We tested the minimum and the maximum (from the 95% confidence intervals) value for each of these variables. Subsequently, using Monte Carlo simulations, multi-way probabilistic sensitivity analyses were performed in which all parameters above mentioned were varied concomitantly taking into account their distribution function. We assumed that event probabilities followed a beta distribution, that costs followed a gamma distribution while relative risks were assumed to have a log-normal distribution [47] .
Validation
The model and simulation data were validated by three CF experts (PD, LL, and AML). Data 
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Results
Base case scenario
Baseline results are presented in 24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 However, we recognize the limitation of using available data on the use of PAP. This test has not been used in the Canadian population, including Quebec. There are therefore uncertainties regarding the applicability of data published from European studies to our population. For example, the A455E mutation is more common (around 3%) in Quebec [48] and has been This study has other limitations. The main limitations of such a simulation study are related to the mapping of a complex reality [49] [50] . Assumptions and simplifications have to be made for some events for which it is difficult to obtain data. For examples, for cases missed by screening, we assumed the same probability to be diagnosed clinically as for the "absence of screening strategy". We are aware that this might not completely reflect the reality. For example, if the missed cases by the NBS are more likely to be atypical cases that are difficult to diagnose based on symptoms (pancreatic sufficient or asymptomatic), the estimated costs 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 per case detected might be overestimated. On the opposite, if the majority of missed cases are symptomatic, the estimated costs per case detected might be underestimated. In the same way, our study did not model the cost of management of family "emotional stress" related to the fact that their child was not diagnosed early or was diagnosed as a carrier. The model has not also considered the costs that could be generated by the follow-up of atypical CF case (CF related metabolic syndrome) detected by NBS. The addition of these costs could increase the cost per case detected by NBS. However, as these atypical CF cases are uncommon and occur primarily in NBS algorithms involving DNA detection, we believe that this would not change the ranking order between options.
An additional limitation of this study has to do with the validity of the parameters used in the simulation model. Parameters were retrieved from an extensive literature search and from experts' opinions. Yet, these parameters especially those related to the performances of the NBS tests or the efficacy of NBS may be specific to the populations under study and might not apply totally to our population. However, we believe that we addressed this issue by performing a large set of sensitivity analyses, which showed that our results are robust.
Another limitation is related to the outcome considered for this study. Indeed, we considered as the main outcome the total number of cases of CF detected (i.e. identified through screening or not). This might not be considered as the most relevant outcome. Quality adjusted-life years (QALY) of the children but also of their parents would certainly be more informative, since, especially for chronic diseases, they are considered as the most relevant health outcome in the economic evaluation field. A better survival and a better quality of life in CF patients detected by newborn screening compared with patients detected clinically are expected. However, an evaluation of QALYs could not be performed, as there is no appropriate instrument to measure utility scores in children under 5 years of age [51] [52] .
A last limitation is related to the use of a single perspective, i.e. the public healthcare perspective. The consideration of the patient/family or societal perspectives could modify the ranking of the options. For example, the addition of the patient/family perspective could disadvantage options that include the second IRT measurement, as an IRT2 measure needs a second blood sample, hence a new contact with the healthcare system.
Despite these limitations, this study suggests that NBS for cystic fibrosis is a cost-effective strategy compared to the absence of NBS in our health care setting. The IRT-PAP newborn screening algorithm with an IRT cutoff at the 96 th percentile is the most cost effective algorithm. Results consist exclusively of cost effectiveness considerations. However, several non-economic are taken into consideration when a decision on a NBS program has to be made, such as laws, already existing newborn screening programs, access to genetic counseling, problem of carrier identification, etc. Nevertheless, besides the fact that the IRT-PAP strategy is the most cost effective, it has other advantages compared to other strategies. It is easy to implement because the analysis is done on a single sample and it allows avoiding the ethic difficulty of unwanted carrier's identification. This CF screening strategy should therefore be considered in any NBS screening program.
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